| Cat. No. |
Product Name |
CAS No. |
Information |
| GY03958 |
Ravidasvir
|
1242087-93-9 |
Ravidasvir (PPI-668;BI 238630) is a potent pan-genotypic HCV NS5A inhibitor with IC50 of 0.12/0.01/1.14 nM for HCV gt-1a/1b/3a in replicon luciferase assay; has been well tolerated and shown high sustained viral response rates as a key component in all-oral combination regimens in multiple human clinical trials. |
| GY02932 |
CTS-1027
|
193022-04-7 |
A potent, selective, broad-spectrum MMP inhibitor with Ki of <9 nM for MMP2, 3, 8, 9, 12, 13 and 14, but not MMP1 and 7; displays little or no activity for other proteinases including caspases, the initiator and effector proteinases of apoptosis; attenuates hepatocyte apoptosis, liver injury and hepatic fibrosis, and is an attractive agent as a potential hepato-protective agent in HCV patients. |
| GY02460 |
Velpatasvir
|
1377049-84-7 |
Velpatasvir (GS-5816) is a second generation, pan-genotypic inhibitor of HCV NS5A, demonstrates a high barrier to resistance in HCV replicon assays. |
| GY07012 |
GSK-2485852
|
1331942-30-3 |
GSK-2485852 (GSK2485852, GSK5852) is a highly potent, selective HCV NS5B polymerase inhibitor with IC50 of 3.0 and 1.6 nM for HCV genotypes 1a and 1b in replicon assay, respectively; displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations P495L, M423T, C316Y, and Y448H; targets NNI palm site 2 of NS5B and inhibits all HCV genotypes. |
| GY07011 |
BMS-929075
|
1217338-97-0 |
BMS-929075 is a highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively; possesses excellent pharmacokinetic parameters across preclinical animal species. |
| GY07010 |
GSK-625433
|
885264-71-1 |
GSK-625433 is a highly potent, selective HCV NS5B polymerase inhibitor for treatment of HCV infection. |
| GY06982 |
Ruzasvir
|
1613081-64-3 |
Ruzasvir is a potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively. |
| GY06933 |
INX-08189
|
1234490-83-5 |
INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay; inhibits viral replication with EC50 of 35 nM, inhibits mutant NS5b S282T mutant replicon with EC90 of 344 nM; orally active. |
| GY06832 |
Coblopasvir
|
1312608-46-0 |
Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection. |
| GY06558 |
Merimepodib
|
198821-22-6 |
Merimepodib (VX-497, VI-21497, MMPD) is a potent, selective, reversible, uncompetitive IMPDH inhibitor with broad-spectrum antiviral activity; inhibits HBV, HCMV, RSV and HSV-1 with IC50 of 0.4, 0.8, 1.1 and 6.3 uM, also inhibits BVDV, VEEV, Coxsackie B3 and Dengue virus with IC50 at low uM level; Merimepodib is 17- to 186-fold more potent than ribavirin against HBV, HCMV, RSV, HSV-1, parainfluenza-3 virus, EMCV, and VEEV infections in cultured cells, also demonstrates additivity when coapplied with IFN-alpha |
$ USD
Select Your Country or Region
